{"result": {"id": "86a7d3f2-cc4a-40f2-b326-f42202a456a9", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>胰岛素<|>ORGANIZATION<|>Insulin, a hormone used in the treatment of diabetes, including multiple daily injections or short-term intensive therapy for blood sugar control>  \n##  \n(\"entity\"<|>噻嗪类利尿剂<|>ORGANIZATION<|>Thiazide diuretics, a class of blood pressure medications that may adversely affect glucose control when used long-term>  \n##  \n(\"entity\"<|>β受体阻滞剂<|>ORGANIZATION<|>Beta-blockers, medications that can mask hypoglycemia symptoms in diabetic patients>  \n##  \n(\"entity\"<|>ASCOT-LLA<|>EVENT<|>Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm, a study demonstrating the benefits of combined blood pressure and lipid-lowering therapy>  \n##  \n(\"entity\"<|>HOPE-3研究<|>EVENT<|>HOPE-3 study, a clinical trial showing the cardiovascular benefits of combined blood pressure and cholesterol management>  \n##  \n(\"entity\"<|>国际多效药物研究-3<|>EVENT<|>Polycap Study-3, an international trial investigating the effects of multi-drug therapy on cardiovascular outcomes>  \n##  \n(\"relationship\"<|>胰岛素<|>2 型糖尿病患者<|>Insulin is used for short-term intensive therapy in newly diagnosed type 2 diabetes patients with severe hyperglycemia<|>8>  \n##  \n(\"relationship\"<|>胰岛素<|>1型糖尿病患者<|>Insulin is the primary treatment for type 1 diabetes patients<|>9>  \n##  \n(\"relationship\"<|>噻嗪类利尿剂<|>高血压患者<|>Thiazide diuretics are used for blood pressure control but may impair glucose metabolism in hypertensive patients<|>6>  \n##  \n(\"relationship\"<|>β受体阻滞剂<|>高血压患者<|>Beta-blockers are used for hypertension but may mask hypoglycemia symptoms in diabetic patients<|>5>  \n##  \n(\"relationship\"<|>ASCOT-LLA<|>高血压患者<|>The ASCOT-LLA trial demonstrated cardiovascular benefits of lipid-lowering therapy in hypertensive patients<|>7>  \n##  \n(\"relationship\"<|>HOPE-3研究<|>高血压患者<|>The HOPE-3 study showed improved cardiovascular outcomes with combined blood pressure and cholesterol management<|>7>  \n##  \n(\"relationship\"<|>国际多效药物研究-3<|>高血压患者<|>The Polycap Study-3 investigated multi-drug approaches for cardiovascular risk reduction in hypertensive patients<|>6>  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558684, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 579, "prompt_tokens": 3237, "total_tokens": 3816, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3136}, "prompt_cache_hit_tokens": 3136, "prompt_cache_miss_tokens": 101}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: �采用 一 日多次胰岛素注射 治疗。\n　　　(6) 空腹血糖>11 mmol/L或 HbA1c≥9%同时 伴明显高血糖症状的新诊断 2 型糖尿病患者 ,可考虑 采用短期(2周~3月)胰岛素强化治疗 , 以尽快控制高 血糖和保留胰岛细胞功能。\n　　　(7)1型糖尿病患者的血糖控制依赖于规律的生 活方式和自我血糖监测基础上的胰岛素治疗。\n　　　(8)在降压治疗过程中 ,需注意降压药对血糖控制 的影响 ,例如大剂量长时间应用噻嗪类利尿剂可能导 致血糖升高 ; β受体阻滞剂可以掩盖心率增快等低血 糖反应。\n\n\n5.3.2  调脂治疗\n\n要点 5I  调脂治疗\n　　　·高血压患者应积极降压联合调脂治疗 ,低密度 脂蛋白胆固醇(low-density lipoprotein cholesterol, LDL-C)是调脂治疗首要靶点( Ⅰ ,A) 。\n　　　· 高血压患者 , 根据 ASCVD 危险分层 , 确定  LDL-C 目标值( Ⅰ ,A) 。降 LDL-C药物治疗 ,首选他  汀类药物( Ⅰ ,A) ,对不能达标患者 ,可加用胆固醇吸  收抑制剂依折麦布或前蛋白转化酶枯草溶菌素 9 ( proprotein  convertase  subtilisin/kexin  type  9,  PCSK9)抑制剂( Ⅰ ,A) 。\n　　　· 高血压患者 ,伴甘油三酯 ≥5.7 mmol/L时 , 为降低胰腺炎风险 ,需启用贝特类或 Omega-3多不 饱和脂肪酸治疗( Ⅱa,B) 。\n\n　　　我国门诊高血压患者中合并血脂异常者占 61.5%[339] 。2015年疾病负担研究显示[340]  ,高血压和 高胆固醇血症是我国居民缺血性心脏病死亡最重要的 两个危险因素。\n　　　高血压患者 ,单纯降压治疗达标 ,并不能最大程度  降低其 ASCVD风险 。近 30余年进行的降脂药物二  级预防研究中[341-343]  ,受试者基线合并高血压的比例  有 20%~50% ,高血压亚组研究结果均提示高血压患  者积 极 降  LDL-C 能 改 善 心 血 管 结 局 事 件 。 在  ASCVD一级预防人群中进行的随机对照研究 , 如盎  格鲁-斯堪的纳维亚心脏终点试验-降脂治疗支(An- glo-Scandinavian cardiac outcome trial-lipid-lowering arm,ASCOT-LLA)[344] 、HOPE-3研究[345] 、国际多效  药物研究-3[346] 等都证实 , 与单纯降压治疗相比 , 降压  联合降 LDL-C治疗 ,可进一步显著降低复合心血管事  件发生率达 20\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>2 型糖尿病患者<|>PERSON<|>Patients diagnosed with type 2 diabetes who may require short-term insulin therapy for high blood sugar control and preservation of pancreatic beta-cell function>  \n##  \n(\"entity\"<|>1型糖尿病患者<|>PERSON<|>Patients with type 1 diabetes whose blood sugar control depends on a structured lifestyle and insulin therapy based on self-monitoring of blood glucose>  \n##  \n(\"entity\"<|>高血压患者<|>PERSON<|>Hypertensive patients who require combined blood pressure and lipid-lowering therapy to reduce cardiovascular risks>  \n##  \n(\"entity\"<|>ASCVD<|>EVENT<|>Atherosclerotic cardiovascular disease, a condition influenced by hypertension and high cholesterol, requiring targeted lipid-lowering therapy>  \n##  \n(\"entity\"<|>LDL-C<|>ORGANIZATION<|>Low-density lipoprotein cholesterol, the primary target for lipid-lowering therapy in hypertensive patients>  \n##  \n(\"entity\"<|>他汀类药物<|>ORGANIZATION<|>Statins, the first-line medication for lowering LDL-C in hypertensive patients>  \n##  \n(\"entity\"<|>依折麦布<|>ORGANIZATION<|>Ezetimibe, a cholesterol absorption inhibitor used in combination with statins for LDL-C reduction>  \n##  \n(\"entity\"<|>PCSK9抑制剂<|>ORGANIZATION<|>PCSK9 inhibitors, a class of drugs used to further lower LDL-C in patients unresponsive to statins>  \n##  \n(\"entity\"<|>贝特类<|>ORGANIZATION<|>Fibrates, used to treat high triglycerides in hypertensive patients to reduce pancreatitis risk>  \n##  \n(\"entity\"<|>Omega-3多不饱和脂肪酸<|>ORGANIZATION<|>Omega-3 polyunsaturated fatty acids, used alongside fibrates for triglyceride management>  \n##  \n(\"relationship\"<|>高血压患者<|>LDL-C<|>Hypertensive patients require LDL-C as the primary target for lipid-lowering therapy<|>8>  \n##  \n(\"relationship\"<|>高血压患者<|>他汀类药物<|>Statins are the first-line treatment for hypertensive patients to lower LDL-C<|>9>  \n##  \n(\"relationship\"<|>高血压患者<|>依折麦布<|>Ezetimibe is used in hypertensive patients when statins alone are insufficient for LDL-C reduction<|>7>  \n##  \n(\"relationship\"<|>高血压患者<|>PCSK9抑制剂<|>PCSK9 inhibitors are prescribed for hypertensive patients who do not achieve LDL-C targets with statins<|>7>  \n##  \n(\"relationship\"<|>高血压患者<|>贝特类<|>Fibrates are used in hypertensive patients with high triglycerides to prevent pancreatitis<|>6>  \n##  \n(\"relationship\"<|>高血压患者<|>Omega-3多不饱和脂肪酸<|>Omega-3 fatty acids are combined with fibrates for triglyceride management in hypertensive patients<|>6>  \n##  \n(\"relationship\"<|>高血压患者<|>ASCVD<|>Hypertension increases the risk of ASCVD, necessitating combined lipid-lowering therapy<|>8>  \n##  \n(\"relationship\"<|>2 型糖尿病患者<|>1型糖尿病患者<|>Both type 2 and type 1 diabetes patients require insulin therapy, though under different conditions<|>4>  \n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_729fb193f2d0bf9762c1afcd4899238fbfa72183a75ee4f5a52456f09489a8b4_v2"}